

IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB00,888-K)

In re the Application of: )  
Sullenger, et al. ) Group Art Unit: 1623  
Serial No.: 10/799,535 ) Examiner: To Be Assigned  
Filed: March 12, 2004 )  
For: Alteration of Sequence of a Target )  
Molecule by Ribozyme Catalyzed )  
Trans-splicing )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313


TRANSMITTAL LETTER

In regard to the above identified application:


1. We are transmitting herewith the attached:
  - a) Information Disclosure Statement;
  - b) Form PTO-1449;
  - c) Postcard.
2. Please charge any additional fees or credit overpayment to Deposit Account No.13-2490.

Respectfully submitted,

MCDONNELL BOEHNEN  
HULBERT & BERGHOFF

  
Patrick G. Gattari  
Reg. No. 39,682

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this 1st day of October, 2004.





FORM PTO-1449  
Commerce (Rev. 2-32)

U. S. Department of  
Patent and Trademark Office

Atty. Docket No.

00-888-K

Serial No.

10/799,535

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several Sheets is Necessary)

**Applicant: Sullenger, et al.**

**Filing Date:**  
March 12, 2004

**Group:**

**U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initial	Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	5,126,260	06-1992	Tuan, et al			
	5,225,337	07-1993	Robertson			
	5,869,254	02-1999	Sullenger			
	5,667,969	09-1997	Sullenger			
	5,225,337	07/06/93	Robertson			
	5,389,514	02/15/95	Taylor			
	5,869,254	02/09/99	Sullenger			
	4,987,017	01/22/91	Cech, et al			
	5,641,673	06/24/97	Haseloff, et al			
	5,498,531	03/12/97	Jarrell			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**FORM PTO-1449**  
**Commerce (Rev. 2-32)**

**U. S. Department of**  
**Patent and Trademark Office**

**Atty. Docket No.**

00-888-K

**Serial No.**

10/799,535

**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(Use several Sheets is Necessary)

**Applicant: Sullenger, et al.**

**Filing Date:**

March 12, 2004

**Group:**


**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Translation	
							Yes	No
		92/13090	08-1992	PCT				
		93/00833	05-1993	WO/PCT				
		90/01731	1990	EPO				
		88/04300	06-1988	WO/PCT				
		92/13089	08-1992	WO/PCT				
		92/07065	08-1992	WO/PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 Commerce (Rev. 2-32)	U. S. Department of Patent and Trademark Office	Atty. Docket No.	Serial No.
 <p data-bbox="272 310 716 384"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p data-bbox="310 422 678 453">(Use several Sheets is Necessary)</p>		00-888-K	10/799,535
		Applicant: Sullenger, et al.	
		Filing Date: March 12, 2004	Group:

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	Weber et al., "Antiviral properties of a dominant negative mutant of the herpes simplex virus type 1 regulatory protein ICP0," <i>Journal of General Virology</i> 73:2955-2961 (1992).
	Rossi, "Controlled, targeted, intracellular expression of ribozymes: progress and problems," <i>TIBTECH</i> 13:301-306 (1995).
	Komatsu et al., "Cross-ligation and exchange reactions catalyzed by hairpin ribozymes," <i>Nucleic Acids Research</i> 21:185-190 (1993).
	Friedman et al., "Expression of a truncated viral <i>trans</i> -activator selectively impedes lytic infection by its cognate virus," <i>Nature</i> 335:452-454 (1988).
	Flanagan and Cech, "Tetrahymena Ribozyme Catalyzes Trans-splicing of Model Oligoribonucleotide Substrates," <i>J. Cell. Biochem.</i> , 12D, 4 April 1998, New York, Pg. 28.
	Cech, "The Chemistry of Self-Splicing RNA and RNA Enzymes," <i>Science</i> 236:1532-1539 (1987).
	Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," <i>Nature</i> 371:619-622 (1994).
	Guthrie, "Messenger RNA Splicing in Yeast: Clues to Why the Spliceosome Is a Ribonucleoprotein," <i>Science</i> 253:157-163 (1991).
	Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of <i>Tetrahymena</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 84:8788-8792 (1987).
	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," <i>Nature</i> 334:585-591 (1988).
	Cech, "Ribozymes and Their Medical Implications," <i>JAMA</i> 260:3030-3034 (1988).
	Jeffries and Symons, "A Catalytic 13-mer Ribozyme," <i>Nucleic Acids Research</i> 17:1371-1377 (1989) (also referred to as Jefferies).
	Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," <i>Aids Research and Human Retroviruses</i> 8:183-189 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
Commerce (Rev. 2-32)

U. S. Department of  
Patent and Trademark Office

Atty. Docket No.

Serial No.

00-888-K

10/799,535

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several Sheets is Necessary)

**Applicant: Sullenger, et al.**

**Filing Date:**  
March 12, 2004

**Group:**

	Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence," <u>Biochemistry</u> 28:4929-4933 (1989).
	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," <u>Nucleic Acids Research</u> 18:299-304 (1990).
	Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis $\delta$ Virus RNA Sequence," <u>Biochemistry</u> 31:16-21 (1992).
	Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme," <u>Cell</u> 35:849-857 (1983).
	Inoue et al., "Intermolecular Exon Ligation of the rRNA Precursor of Tetrahymena: Oligonucleotides Can Function as a 5' Exons," <u>Cell</u> 43:431-437 (1985)
	Bruzik et al., "Spliced leader RNAs from Lower eukaryotes are <i>trans</i> -spliced in mammalian cells," <u>Letters to Nature</u> 360:692-695 (1992)
	Cech et al., " <i>In Vitro</i> Splicing of the Ribosomal RNA Precursor of Tetrahymena: Involvement of a Guanosine Nucleotide in the Excision of the Intervening Sequence," <u>Cell</u> 27:487-496 (1981).
	Kruger et al., "Self-Splicing RNA: Autoexcision and Autocyclization of the Ribosomal RNA Intervening Sequence of Tetrahymena," <u>Cell</u> 31:147-157 (1982).
	Rossi, "Controlled, targeted, intracellular expression of ribozymes: progress and problems," <u>TIBTECH</u> 13:301-306 (1995).
	Been and Cech, "One Binding Site Determines Sequence Specificity of Tetrahymena Pre-rRNA Self-Splicing, Trans-Splicing and RNA Enzyme Activity," <u>Cell</u> 47:207-216 (1986)
	Cech, "Ribozyme Engineering," <u>Current Opinion in Structural Biology</u> 2:605-609 (1992)
	Dzierzak et al., "Lineage-specific Expression of a Human $\beta$ -globin Gene in Murine Bone Marrow Transplant Recipients Reconstituted with Retrovirus-transduced Stem Cells," <u>Nature</u> 331:35-41 (1989).
	Konarska et al., " <i>Trans</i> Splicing of mRNA Precursors in Vitro," <u>Cell</u> 42:165-171 (1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
Commerce (Rev. 2-32)

U. S. Department of  
Patent and Trademark Office

Atty. Docket No.

Serial No.

00-888-K

10/799,535

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several Sheets is Necessary)

**Applicant: Sullenger, et al.**

**Filing Date:**  
March 12, 2004

**Group:**

	Kruger et al., "Self-Splicing RNA: Autoexcision and Autocyclization of the Ribosomal RNA Intervening Sequence of <i>Tetrahymena</i> ," <u>Cell</u> 31:147-157 (1982).
	Malim et al., "Functional Dissection of the HIV-1 Rev <i>Trans</i> -Activator – Derivation of a <i>Trans</i> -Dominant Repressor of Rev Function" <u>Cell</u> 58:205-214 (1989).
	Morgan and Anderson, "Human Gene Therapy," <u>Annu. Rev. Biochem.</u> 62:191-217 (1993).
	Murphy and Cech, "Alteration of Substrate Specificity for the Endoribonucleolytic Cleavage of RNA by the <i>Tetrahymena</i> Ribozyme," <u>Proc. Natl. Acad. Sci. USA</u> 86:9218-9222 (1989).
	Price and Cech, "Coupling of <i>Tetrahymena</i> Ribosomal RNA Splicing to $\beta$ -Galactosidase Expression in <i>Escherichia coli</i> ," <u>Science</u> 228:719-722 (1985).
	Price and Cech, "Determinants of the 3' Splice Site for Self-splicing of the <i>Tetrahymena</i> pre-rRNA," <u>Genes &amp; Development</u> 2:1439-1447 (1988).
	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <u>Science</u> 247:1222-1225 (1990).
	Smith et al., "Development of a <i>lacZ</i> Marked WEHI-3B D <sup>+</sup> Murine Leukemic Cell Line as an <i>In-Vivo</i> Model of Acute Non-Lymphocytic Leukemia," <u>Leukemia</u> 7:310-317 (1993).
	Solnick, " <i>Trans</i> Splicing of mRNA Precursors," <u>Cell</u> 42:157-164 (1985).
	Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," <u>Cell</u> 63:601-608 (1990).
	Trono et al., "HIV-1 Gag Mutants Can Dominantly Interfere with the Replication of the Wild-type Virus," <u>Cell</u> 59:113-120 (1989).
	Tsuchihashi et al., "Protein Enhancement of Hammerhead Ribozyme Catalysis," <u>Science</u> 262:99-102 (1993).
	van der Veen et al., "Excised Group II Introns in Yeast Mitochondria are Lariats and Can Be Formed by Self-splicing <i>In Vitro</i> ," <u>Cell</u> 44:225-234 (1986).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
Commerce (Rev. 2-32)

U. S. Department of  
Patent and Trademark Office

Atty. Docket No.

00-888-K

Serial No.

10/799,535

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several Sheets is Necessary)

**Applicant: Sullenger, et al.**

**Filing Date:**

March 12, 2004

**Group:**

Waring et al., "The Tetrahymena rRNA Intron Self-Splices in E. Coli: In Vivo Evidence for the Importance of Key Base-Paired Regions of RNA for RNA Enzyme Function," Cell 40:371-380 (1985).

Weber et al., "Antiviral properties of a dominant negative mutant of the herpes simplex virus type 1 regulatory protein ICP0," Journal of General Virology 73:2955-2961 (1992).

Zaug and Cech, "The Intervening Sequence RNA of *Tetrahymena* Is a Enzyme," Science 231:470-475 (1986).

Zaug et al., "The *Tetrahymena* Ribozyme Acts Like an RNA Restriction Endonuclease," Nature 324:429-433 (1986).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.